News | Prostate Cancer | October 16, 2019

Theragnostics’ novel PET tracer, GalliProst, will help visualize prostate cancer to enable personalized treatment

GE Healthcare and Theragnostics Partnering on PSMA PET/CT Imaging Agent

October 16, 2019 — GE Healthcare and Theragnostics have entered into a global commercial partnership for a new prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) imaging agent. Theragnostics will lead the development of the tracer, GalliProst, while GE Healthcare will lead all pre-approval commercial preparations and, as and when approval is received, all subsequent commercial and distribution activities.

Today, prostate cancer is the fourth largest cancer type, accounting for just over 1.2 million new cases and over 350,000 fatalities around the globe in 2018. The diagnostic workflow for detecting prostate cancer starts through a blood test or biopsy, after which patients are typically referred for PET/CT imaging so that radiologists can see their tumor, lymph nodes and any metastasis in order to decide the appropriate course of treatment. The ‘heatmap’ style image enabled by the new tracer shows the precise location and intensity of PSMA, which is expressed on the surface of prostate cancer cells.

Theragnostics has reported data from a phase two clinical study which met its primary and secondary endpoints, demonstrating that one third of newly diagnosed prostate cancer patients — and more than 50 percent of patients with biochemically recurrent disease — had their treatment plans modified as a result of a GalliProst scan. The change in patient management increased to 75 percent in a post-radical radiotherapy setting.

This marks the second agreement between Theragnostics and GE Healthcare, following an agreement in 2018 for a diagnostic tracer for imaging kidney function and scarring. 

For more information: www.gehealthcare.com, www.theragnostics.com


Related Content

News | PET Imaging

May 30, 2025 — GE HealthCare recently announced that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) ...

Time May 30, 2025
arrow
News | Breast Imaging

May 13, 2025 — In one of the larger studies of its kind, researchers have identified six breast texture patterns that ...

Time May 16, 2025
arrow
News | Nuclear Imaging

May 5, 2025 — GE HealthCare recently announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance ...

Time May 06, 2025
arrow
News | Computed Tomography (CT)

Feb. 25, 2025 —Stratasys Ltd. and Siemens Healthineers recently presented the results of a joint research effort that ...

Time March 04, 2025
arrow
News | Artificial Intelligence

Feb. 4, 2025 — Riverain Technologies recently announced it expanded across eight countries in 2024 and added nearly 50 ...

Time February 04, 2025
arrow
News | Artificial Intelligence

Dec. 12, 2024 — At RSNA 2024, Careverse officially made its debut, exhibiting in the AI Showcase area, sharing its ...

Time December 18, 2024
arrow
News | Artificial Intelligence

Dec. 17, 2024 — Radin Health, a provider of advanced radiology AI-Powered solutions, highlighted its All-in-One ...

Time December 18, 2024
arrow
News | Computed Tomography (CT)

Dec. 3, 2024 — During RSNA '24, GE HealthCare announced the 510(k) submission to the U.S. Food and Drug Administration ...

Time December 18, 2024
arrow
News | Mammography

Dec. 5, 2024 — At RSNA 2024, Lunit and Volpara Health announced their unified vision, focusing on a comprehensive ...

Time December 05, 2024
arrow
News | Ultrasound Imaging

Dec. 1, 2024 — At RSNA 2024, Siemens Healthineers introduced Acuson Sequoia 3.51, a major software and hardware update ...

Time December 04, 2024
arrow
Subscribe Now